STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK…
Category: GSK
4 takeaways from STAT’s story on the development of malaria vaccines
For the first time, the world is starting to roll out malaria vaccines to children…
CDC advisory panel opts for a go-slow approach on expanding usage of RSV vaccines
Makers of RSV vaccines for older adults saw their plans to try to expand usage…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: During the pandemic, were great vaccines bad business? A company-by-company review
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people…
STAT+: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling
A commonly prescribed medication for children’s asthma is disappearing from pharmacists’ shelves, forcing parents and…
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure
Here are two things that are true. The world needs more effective flu vaccines. And…